FDC of Indacaterol Maleate and Glycopyrronium Bromide Inhalation Dual Action for Long-Term COPD

Introduction

The FDC of Indacaterol Maleate and Glycopyrronium Bromide inhalation combines the benefits of a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), which provides sustained bronchodilation for 24 hours, improving airflow and reducing symptoms in COPD patients. This combination works synergistically to relax airway muscles, ease breathing, and improve overall lung function.

Mechanism of Action

• Indacaterol Maleate is an ultra-long-acting beta2-adrenergic agonist that stimulates beta2 receptors in airway smooth muscle, causing muscle relaxation and airway dilation. It activates adenylate cyclase, increasing cyclic AMP (cAMP) levels, which leads to prolonged bronchodilation and rapid onset of action within minutes.
  
  

• Glycopyrronium Bromide (Glycopyrrolate IP) is a long-acting muscarinic antagonist that selectively blocks M3 muscarinic receptors responsible for bronchoconstriction. By inhibiting acetylcholine binding, it prevents parasympathetic nerve impulses, leading to decreased muscle tone and airway relaxation. Glycopyrronium also reduces acetylcholine release from epithelial cells which contributes to synergistic bronchodilation when combined with Indacaterol.

Together, this FDC produces a synergistic improvement in bronchodilation by elevating cAMP levels in airway smooth muscle and epithelium while inhibiting acetylcholine-mediated bronchoconstriction.

Uses and Indications

• Maintenance treatment of chronic obstructive pulmonary disease (COPD)

• To improve lung function and reduce symptoms such as breathlessness and airflow obstruction

• Prevention of exacerbations in moderate-to-severe COPD patients

Efficacy and Clinical Evidence

Clinical studies demonstrate that the combination of Indacaterol Maleate and Glycopyrronium Bromide provides superior bronchodilation compared to monotherapy. It improves lung function, reduces exacerbation rates, and enhances patient quality of life. The 24-hour duration of action allows once-daily dosing, improving treatment adherence.

Side Effects and Safety Profile

Common side effects may include:

• Dry mouth

• Cough

• Headache

• Nasopharyngitis

The medication is generally well tolerated with low incidence of cardiovascular events due to the selective receptor action of both components.

Contraindications and Precautions

• Hypersensitivity to Indacaterol, Glycopyrronium, or any excipients

• Use with caution in patients with cardiovascular disorders, narrow-angle glaucoma, urinary retention

• Not indicated for acute bronchospasm or asthma exacerbations

Drug Interactions

• Beta-blockers may reduce the effectiveness of Indacaterol

• Other anticholinergic agents can increase side effects of Glycopyrronium

• Caution with CYP3A4 inhibitors due to metabolism of Indacaterol

Warnings and Regulatory Status

• Approved by major regulatory bodies for COPD management

• Warnings include potential cardiovascular risks and paradoxical bronchospasm

• Regular monitoring advised for patients with cardiovascular comorbidities

Patient Advice and Tips

• Use the inhaler device properly to ensure adequate dose delivery

• Rinse mouth after inhalation to reduce risk of oral infections

• Do not use for immediate relief of sudden breathing problems

• Adhere to prescribed dosing regimen

Availability

GLYCOPRESS INDUS, containing Indacaterol Maleate and Glycopyrronium Bromide powder for inhalation, is available in various markets including India, often as a branded product from pharmaceutical companies like Steris Healthcare Pvt Ltd.

Why Choose Steris Healthcare Pvt Ltd?

Steris Healthcare Pvt Ltd is known for manufacturing high-quality respiratory medicines, ensuring strict adherence to regulatory standards, providing reliable supply chains, and supporting patient education for optimal disease management.

Frequently Asked Questions 

1. What is the main advantage of the fixed-dose combination (FDC) of Indacaterol maleate and glycopyrronium bromide inhalation?
   It offers dual bronchodilation through LABA and LAMA mechanisms, providing enhanced, long-lasting relief for COPD patients.
   
   

2. Can glycopyrronium bromide be used alone?
   Yes, glycopyrronium bromide is available as monotherapy in formulations like oral solution or inhalation powder for COPD management.
   
   

3. How quickly does GLYCOPRESS INDUS start working?
   Indacaterol component acts within minutes, while full bronchodilatory effect peaks within hours and lasts over 24 hours.
   
   

4. Is this medication safe for all COPD patients?
   It is generally safe but should be used cautiously in patients with certain cardiovascular issues or glaucoma.
   
   

5. Where can I buy GLYCOPRESS INDUS?
   It is available through pharmacies and licensed distributors, often manufactured by Steris Healthcare Pvt Ltd.

Conclusion

The FDC of Indacaterol Maleate and Glycopyrronium Bromide inhalation (GLYCOPRESS INDUS) is a powerful and well-researched treatment option for COPD. Its combination of rapid-onset, long-acting bronchodilation with a favorable safety profile makes it an excellent choice. The inclusion of glycopyrronium bromide oral solution and standalone glycopyrronium bromide products further extends therapeutic options in respiratory care. Choosing Steris Healthcare Pvt Ltd ensures access to quality medication backed by clinical efficacy and regulatory compliance.